RSS-Feed abonnieren
DOI: 10.1055/s-0031-1296426
Pharmacokinetics Characterization of Liposomal Amphotericin B: Investigation of Clearance Process and Drug Interaction Potential
Publikationsverlauf
Publikationsdatum:
13. Dezember 2011 (online)
![](https://www.thieme-connect.de/media/amf/200909/lookinside/thumbnails/10.1055-s-0031-1296426-1.jpg)
Abstract
AmBisome®, a liposomal formulation of amphotericin B (CAS 1397-89-3, L-AMB), shows different pharmacokinetics from the conventional formulation, amphotericin B deoxycholate (D-AMB). To characterize the clearance process of L-AMB, the form in which it exists in rat plasma, pharmacokinetics in hepatic or renal failure rats, cellular distribution in rat liver, and placental and milk transfer in rat were investigated. Furthermore, to predict the drug-drug interaction, in vitro metabolism of amphotericin B (AMB) by rat, dog and human liver S9 fraction, and effects of L-AMB on drug-metabolizing enzyme systems were investigated. L-AMB was found to exist stably as a liposomal form in rat plasma without any notable transfer to milk or fetus in rats. After administration to hepatic failure rats, the CLtot of AMB decreased to 1/4 and the Vdss decreased to 1/8 compared with the control rat case. In contrast, after administration to renal failure rats, plasma AUC of AMB did not significantly change compared with sham-operated rats. These data suggest that hepatic clearance is the main determinant of the CLtot for L-AMB. In rat liver, L-AMB was distributed mainly to non-parenchymal cells. In the in vitro metabolism study using liver S9 fraction, no metabolite peaks were observed. After repeated administration of L-AMB to rats, there was no change in parameters related to the drug-metabolising enzyme system in liver microsomes. These data demonstrate that clinically significant metabolism-based drug interaction with L-AMB should be less likely.
-
References
- 1 Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis. 2005; 41 (4) 521-6
- 2 Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new “gold standard”. Clin Infect Dis. 2003; 37 (3) 415-25
- 3 Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000; 13 (2) 236-301
- 4 Vanden Bossche H, Dromer F, Improvisi I, Lozano-Chiu M, Rex JH, Sanglard D. Antifungal drug resistance in pathogenic fungi. Med Mycol. 1998; 36 (Suppl 1) 119-28
- 5 Ellis D. Amphotericin B: spectrum and resistance. J Antimi-crob Chemother. 2002; 49 (Suppl 1) 7-10
- 6 Abu-Salah KM. Amphotericin B: an update. Br J Biomed Sci. 1996; 53 (2) 122-33
- 7 Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol. 1998; 44: 343-500
- 8 Maniwa T, Yamamoto Y. [Antifungal activity and clinical efficacy of liposomal amphotericin B (AmBisome)]. Nippon Yakurigaku Zasshi. 2007; 129 (2) 129-34
- 9 Boswell GW, Buell D, Bekersky I. AmBisome (liposomal amphotericin B): a comparative review. J Clin Pharmacol. 1998; 38 (7) 583-92
- 10 Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother. 2002; 49 (Suppl 1) 21-30
- 11 Alpini G, Phillips JO, Vroman B, LaRusso NF. Recent advances in the isolation of liver cells. Hepatology. 1994; 20 (2) 494-514
- 12 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193 (1) 265-75
- 13 Omura T, Sato R. The Carbon Monoxide-Binding Pigment of Liver Microsomes. I. Evidence for Its Hemoprotein Nature. J Biol Chem. 1964; 239: 2370-8
- 14 Vermilion JL, Coon MJ. Highly purified detergent-solubilized NADPH-cytochrome P-450 reductase from phenobarbital-induced rat liver microsomes. Biochem Biophys Res Commun. 1974; 60 (4) 1315-22
- 15 Jayyosi Z, Knoble D, Muc M, Erick J, Thomas PE, Kelley M. Cytochrome P-450 2E1 is not the sole catalyst of chlorzoxazone hydroxylation in rat liver microsomes. off. J Pharmacol Exp Ther. 1995; 273 (3) 1156-61
- 16 Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother. 2002; 46 (3) 834-40
- 17 Juliano RL. Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions. Adv Drug Deliv Rev. 1988; 2: 31-54
- 18 Townsend RW, Zutshi A, Bekersky I. Biodistribution of 4-[(14)C]cholesterol-AmBisome following a single intravenous administration to rats. Drug Metab Dispos. 2001; 29 (5) 681-5
- 19 Fielding RM, Smith PC, Wang LH, Porter J, Guo LS. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother. 1991; 35 (6) 1208-13
- 20 Dean JL, Wolf JE, Ranzini AC, Laughlin MA. Use of amphotericin B during pregnancy: case report and review. Clin Infect Dis. 1994; 18 (3) 364-68
- 21 Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993; 10 (7) 1093-5
- 22 Gregoriadis G. Overview of liposomes. J Antimicrob Chemother. 1991; 28 (Suppl B) 39-48
- 23 Bekersky I, Boswell GW, Hiles R, Fielding RM, Buell D, Walsh TJ. Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats. Pharm Res. 2000; 17 (12) 1494-1502
- 24 Kume Y, Maeda F, Harashima H, Kiwada H. Saturable, non-Michaelis-Menten uptake of liposomes by the reticuloendothelial system. J Pharm Pharmacol. 1991; 43 (3) 162-6
- 25 Harashima H. Pharmacokinetic studies on the drug delivery system using liposomes. Yakubutsu Dotai. 1995; 10 (4) 566-75
- 26 Chow DD, Essien HE, Padki MM, Hwang KJ. Targeting small unilamellar liposomes to hepatic parenchymal cells by dose effect. J Pharmacol Exp Ther. 1989; 248 (2) 506-13
- 27 Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 2002; 46 (3) 828-33
- 28 Inselmann G, Volkmann A, Heidemann HT. Comparison of the effects of liposomal amphotericin B and conventional amphotericin B on propafenone metabolism and hepatic cytochrome P-450 in rats. Antimicrob Agents Chemother. 2000; 44 (1) 131-3